http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20010082501-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D233-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D249-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D277-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D231-12 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D333-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D235-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D521-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-551 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-454 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D277-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-426 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-427 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D277-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D277-20 |
| filingDate | 1998-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2001-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20010082501-A |
| titleOfInvention | 4-Aminothiazole Derivatives, Their Preparation and Their Use as Inhibitors of Cyclin-dependent Kinases |
| abstract | The present invention provides a pharmaceutical composition comprising an aminothiazole compound represented by the following formula (I) inhibiting a cyclin-dependent kinase (CDKs) such as CDK1, CDK2, CDK4 and CDK6, a pharmaceutically acceptable salt of said compound, ≪ / RTI > or a pharmacologically active metabolite thereof.n n n [Chemical Formula 1]n n n n n n n n Wherein, R 1 is C 1-6 - alkyl; C 1-6 -alkenyl; C 1-6 -alkynyl; C 1-6 -alkoxyl; C 1-6 -alcohols; A carbocyclic or heterocyclic cycloalkyl which is a monocycle or a fused or unfused polycycle; A carbocyclic or heterocyclic aryl which is a monocycle or a fused or unfused polycycle; Carbonyl; ether; (C 1-6 -alkyl) -carbonyl; (Ci- 6 -alkyl) -aryl; (Ci- 6 -alkyl) -cycloalkyl; (C 1-6 -alkyl) - (C 1-6 -alkoxyl); Aryl- ( C1-6 -alkoxyl); Thioether; Thiol; And sulfonyl; or a heterocyclic group,n n n When R < 1 > is substituted, each substituent is independently selected from the group consisting of halogen; Haloalkyl; C 1-6 -alkyl; C 1-6 -alkenyl; C 1-6 -alkynyl; Hydroxyl; C 1-6 -alkoxyl; Amino; Nitro; Thiol; Thioether; immigrant; Cyano; Amido; Phosphoneate; Phosphine; Carboxyl; Thiocarbonyl; Sulfonyl; Sulfonamide; Ketones; Aldehyde; ester; Oxygen; A carbocyclic or heterocyclic cycloalkyl which is a monocycle or a fused or unfused polycycle; Or a carbocyclic or heterocyclic aryl which is a monocycle or a fused or unfused polycycle;n n n R 2 is a ring structure with substituents in the region adjacent to the coupling point mono cycle or fused or non-fused poly-cycle of carbonate cyclic or heterocyclic ring system wherein said ring system is there is optionally further substituted, wherein the R 2 Each substituent is independently selected from the group consisting of halogen; Haloalkyl; C 1-6 -alkyl; C 1-6 -alkenyl; C 1-6 -alkynyl; Hydroxyl; C 1-6 -alkoxyl; Amino; Nitro; Thiol; Thioether; immigrant; Cyano; Amido; Phosphoneate; Phosphine; Carboxyl; Thiocarbonyl; Sulfonyl; Sulfonamide; Ketones; Aldehyde; ester; Oxygen; A carbocyclic or heterocyclic cycloalkyl which is a monocycle or a fused or unfused polycycle; Or a carbocyclic or heterocyclic aryl which is a monocycle or a fused or unfused polycycle.n n n The present invention also relates to methods of using pharmaceutical compositions comprising such compounds for therapeutic or prophylactic purposes, and methods of treating such malignant diseases and other diseases by administering such compounds in a charged amount. |
| priorityDate | 1997-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 914.